CSL Limited (ASX: CSL) is Australia’s largest (and some might say best) healthcare company, specialising in biopharmaceuticals. Founded in the late 1900s as the Commonwealth Serum Laboratories, CSL was sold by the Australian Government to Australian investors via the share market in 1994 at $2.30 per share, at which time it doubled its size through an international acquisition. CSL is a global leader in blood plasma vaccines (think: the flu) and antivenoms, providing relief for potentially life-threatening medical conditions.
You would think CSL Limited (ASX:CSL) shares had done enough for ASX investors, rising from $30 in 2011 to over $190 today. Can the CSL share price go higher?
Australia’s population is ageing and companies like Cochlear Limited (ASX: COH) and CSL Limited (ASX: CSL) could stand to benefit.
With the All Ordinaries Index (INDEXASX: XAO)(ASX: XAO) down 1% some investors might be asking ‘what on earth has happened to OncoSil Medical Ltd (ASX: OSL)’?
Australia’s share market, or the All Ordinaries Index (INDEXASX:XAO)(ASX:XAO), is currently up 0.75% at lunch.
Nanosonics Ltd (ASX:NAN) and CSL Ltd (ASX:CSL) shares could keep beating the S&P/ASX 200 (INDEXASX:XJO) index.
The BHP Group Ltd (ASX:BHP) share price has outperformed the S&P/ASX 200 (INDEXASX:XJO) (^AXJO) since the beginning of 2019.
The CSL Limited (ASX:CSL) share price got knocked around 4% today after the biopharmaceutical giant released its latest round of financial results to investors.
Australia’s share market, or the All Ordinaries Index (INDEXASX:XAO)(ASX:XAO), is currently up 0.24% at lunch.
The ResMed Inc (ASX:RMD) share price is down another 9.2% so far today, but there are reasons to remain positive about the healthcare business.
